4582 SymBio Pharmaceuticals
- 153
- -1-0.65%
SymBio Pharmaceuticals News
Synbio Pharmaceuticals Research Memo (12): Aiming to grow as a global specialty pharma as a long-term goal
■Future outlook 2. Long-term strategy Synbio Pharmaceuticals ＜4582＞ aims to grow as a global specialty pharma as a long-term goal, and wants to increase domestic and overseas sales ratios of 50%, respectively, by 2030. Domestically, in addition to “treaxine (R),” it is a strategy to expand sales by listing new items and BCVs to be introduced in the future, and to expand sales overseas by launching at least 2 items with BCV. As a BCV platform deployment
Synbio Pharmaceuticals Research Memo (10): Policy to secure cash on hand of 5.5 to 6.5 billion yen as a guide
■Performance Trends 2. Financial Status The total assets of Synbio Pharmaceuticals＜4582＞ at the end of the 2023/12 fiscal year decreased 2,263 million yen from the end of the previous fiscal year to 8,170 million yen. Looking at the main factors of change, cash and deposits increased by 234 million yen in current assets, while accounts receivable decreased by 1,171 million yen. As for fixed assets, tangible fixed assets decreased by 69 million yen and software by 222 million yen, respectively, due to the recording of impairment losses, and deferred tax assets decreased by 744 million yen. What is the total debt
Synbio Pharmaceuticals Research Memo (9): Sales declined drastically in the 2023/12 fiscal year due to the penetration of generic drugs and falling drug prices
■Earnings Trends 1. Financial Overview for the Fiscal Year Ending 2023/12 The consolidated financial results for the fiscal year ending 2023/12 of Synbio Pharmaceuticals (4582) were sales down 44.1% from the previous fiscal year to 5,589 million yen, operating losses of 811 million yen (profit of 1,963 million yen in the previous fiscal year), ordinary losses of 736 million yen (same profit of 1,999 million yen), and net loss attributable to parent company shareholders was 1,962 million yen (profit of 1,179 million yen) for the first time in 4 periods, 3 The loss was recorded for the first time in the period. Sales are new models
Synbio Pharmaceuticals Research Memo (8): Rigocertib is exploring development possibilities in combination with other agents
■Other pipeline trends for Synbio Pharmaceuticals＜4582＞ 2. “Ligosertib” (injection/oral agent) and “rigocertib” are anticancer drug candidates having a unique multi-kinase inhibitory effect (action that causes cancer cells to die by inhibiting multiple kinases involved in the proliferation, invasion, and metastasis of cancer cells). An international joint phase 3 clinical trial (INSPIRE trial) for myelodysplastic syndrome (MDS) was conducted at the introducer Onconova, 2020
Synbio Pharmaceuticals Research Memo (7): Market share of treaxine (R) is expected to decline moderately due to entry into generic pharmaceuticals
■Other pipeline trends for Synbio Pharmaceuticals＜4582＞ 1. “Treaxine (R)” (generic name: bendamustine hydrochloride) and “treaxine (R)” are anticancer drugs for malignant lymphoma. Malignant lymphoma is a disease in which lymphocytes, which are a type of white blood cell, become cancerous (tumours) and form lumps (tumors) in lymph nodes and organs, and also occurs from lymph nodes distributed throughout the body and organs other than lymph nodes (stomach, intestines, thyroid, spinal cord, lungs, liver, skin, eyes, etc.). Of blood cancer
Synbio Pharmaceuticals Research Memo (4): BCV development risk reduction, aiming to obtain approval for 2 indications by 2030 (1)
■Synbio Pharmaceuticals＜4582＞ BCV Development Strategy 2. The development pipeline BCV is currently being developed while conducting joint research with academia in multiple areas such as AdV infections, brain tumors, hematological tumors, and neurodegenerative diseases after hematopoietic stem cell transplantation. Of these, it was announced in 2023/5 that PoC was established in a phase 2 clinical trial targeting ADV infection after hematopoietic stem cell transplantation. Low development risk in other disease areas due to the establishment of POC
Synbio Pharmaceuticals Research Memo (2): Bio-ventures that develop targets in the “cancer, blood, and viral infections” area
■Company Overview Synbio Pharmaceuticals＜4582＞ is a biotechnology venture founded by current President and CEO Yoshida Fuminori (Yoshida Fuminori) in 2005/3. The basic policy of the business strategy is to develop and provide new drugs to fill the “blank treatment area” where development has been postponed due to the small number of patients, and in particular, it focuses on the fields of “cancer, blood, viral infections,” where medical needs are high, and introduces development candidates that have acquired POC in humans to the clinical trial stage
Synbio Pharmaceutical---With the establishment of POC for BCV, multiple clinical trials will begin in 2025 and development will be accelerated
Synbio Pharmaceuticals＜4582＞ is a biotechnology venture that targets the “cancer, blood, virus infection” area with high unmet medical needs*1 and promotes efficient business operations from the clinical trial stage. In addition to “treaxine (R)” (treatment for malignant lymphoma), which has already been commercialized, the antiviral drug “brincidofovir” introduced from Chimerix in the US, and Oncono
Synbio Pharmaceutical---Clinical trial targeting CMV infection after hematopoietic stem cell transplantation in ATHENA trial begins
Synbio Pharmaceuticals ＜4582＞ announced on the 8th that it has begun clinical trials targeting cytomegalovirus infection (CMV infection) after hematopoietic stem cell transplantation in a phase 2a clinical trial (ATHENA test) with the injectable brincidofovir. The company plans to complete the injectable brincidofovir phase 2a clinical trial targeting adenovirus infection (AdV infection) after hematopoietic stem cell transplantation in the first half of the 2024/12 fiscal year. This is the second indication
GMOTECH, GMOTECH, etc.
＜3628＞Data HR revised downward, sales forecast for the current fiscal year 4.90 billion yen ← 6.300 billion yen ＜4579＞LaQuoria Drug Discovery Phase I Clinical Trials Begin in Australia ＜4582＞Clinical Trials Targeting Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation in Phase IIa Clinical Trial (ATHENA Test) with the Synbio Pharmaceutical Injection Brincidofovir Begin Clinical Trials Targeting Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation ＜6026＞GMOTECH Upward Revised for the Current Fiscal Year ＜6026＞GMOTECH Upward Revised for the Current Fiscal Year Forecast 1,040 million yen ←
SymBio Pharmaceuticals: Quarterly Report - 20th Quarter 1 (2024/01/01 - 2024/03/31)
SymBio Pharmaceuticals: Confirmation
Synbio Pharmaceuticals--Continued promotion of research and development activities despite 1Q sales decline
Synbio Pharmaceuticals ＜4582＞ announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 7th. Net sales decreased 61.3% from the same period last year to 597 million yen, operating loss was 806 million yen (profit of 51 million yen in the same period last year), ordinary loss was 727 million yen (profit of 0.48 billion yen), and quarterly net loss attributable to parent company shareholders was 777 million yen (same profit of 0.4 billion yen). Currently, treaxine (R) intravenous infusion solution 100 mg/4 mL [RTD (Rea)
Medlec, Note, etc. [Emerging Markets Press Release]
＜3645＞Medical Net Shareholder Benefit System＜4586＞Medlec 28th Stock Acquisition Rights (with exercise price amendment clause) number of shares issued from the 7th, 875,000 shares ＜4582＞ Symbio Pharma downward revisions, operating loss forecast for the current fiscal year △ 3.702 billion yen ← △ 2,837 billion yen ＜4978＞Reprocel downward revision, previous fiscal year operating loss forecast △ 409 million yen ←△ 110 million yen ＜5243＞net subsidiary established and new business started < 7372 > below décolletage HD
Nintendo's 24/3 operating profit increased 4.9% to 528.9 billion yen, 25/3 forecast decreased 24.4% to 400 billion yen
The financial results for the fiscal year ending 2024/3 announced by Nintendo ＜7974＞ were sales of 1.671,865 billion yen, up 4.4% from the previous fiscal year, and operating profit of 528.941 billion yen, up 4.9% from the same period. As for the financial results for the fiscal year ending 2025/3, we plan that sales will decrease 19.3% from the previous fiscal year to 1.35 trillion yen, and operating profit will decrease 24.4% to 400 billion yen. Sales related to the main engine “Nintendo Switch,” which has reached its 8th year of sale, will slow down. It falls below consensus (about 490 billion yen). [Positive Assessment] <61
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 5/7)
[Good news] ---- ---- ■Maruha Nichiro [Tokyo Stock Exchange P] Current account profit increased by 3%, dividends for the first fiscal year increased by 15 yen, and dividends increased by 15 yen for the current fiscal year. ■Takamatsu Construction Group [Tokyo Stock Exchange P] revised its previous fiscal year accounts upward by 9%. ■Yamato [Tokyo Stock Exchange S]'s current financial results increased 42% and dividends increased by 8 yen. ■Interspace [Tokyo Stock Exchange S] revised its current account for the first half of the year 57%, and the full year also increased. ■Prima Ham
SymBio Pharmaceuticals Sees FY Loss Y3.63B
SymBio Pharmaceuticals Ltd. also released the following forecasts: GROUP Year Ending Dec 2024 Revenue Y2.62 bln Operating Profit (Y3.70 bln) Preta
SymBio Pharmaceuticals: Notice regarding revisions to the full-year earnings forecast for the fiscal year ending 2024/12
SymBio Pharmaceuticals: Summary of Financial Results for the 1st Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
JFEHD, Yokogawa Electric, Nintendo, Kawasaki Ships (7 days)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/7 (Tue) ＜130A＞VIS ＜1333＞Maruha Nichiro ＜1723＞NEC ＜2003＞Nitto Fuji ＜2009＞Torigoe Powder ＜2053＞Chubukai ＜2281＞Prima Ham ＜2344＞Heian Rei ＜290
Analysis
Price Target
No Data
